Ariane at ASTRO 2025 – San Francisco

/in , , /by

28 September – 1 October 2025
Moscone Centre, San Francisco

Ariane was proud to attend the American Society for Radiation Oncology (ASTRO) Annual Conference 2025, one of the world’s leading gatherings in the field of radiation oncology. Representing Ariane, Mark Davies-Cousins, VP International Sales, was on hand to connect with clinicians and partners from across the globe.

A highlight of the conference was an insightful presentation from Dr. Barbet (Macon & Villeurbanne), who shared a detailed update on the latest results from the OPERA trial, reinforcing the growing clinical evidence for Papillon CXB.

Mark also met with clinicians from New York and Hong Kong, both of whom will soon begin offering Papillon CXB as part of their planned cancer treatment programmes — a clear signal of the continued global expansion of this targeted therapy.

We are delighted to see Papillon CXB gaining momentum internationally and thank all partners and clinicians who continue to support and advocate for this innovative approach to cancer treatment.

For more information on Papillon CXB and its clinical applications, please contact:

Mark Davies-Cousins
VP International Sales
mark.davies@arianemedicalsystems.com

Papillon CXB Training at Clatterbridge Cancer Centre

/in , , /by

24–25 September 2025
The Clatterbridge Cancer Centre, Liverpool

For the 19th consecutive year, the Clatterbridge Cancer Centre in Liverpool proudly hosted its renowned Papillon CXB Training event. This two-day programme brought together clinicians from across the globe, offering both presentations and in-context clinical examples from some of the leading advocates of the Papillon technique.

The event opened with an insightful retrospective from Prof. Arthur Sun Myint, who highlighted the ongoing clinical benefits of CXB and outlined the clear advantages of the treatment moving forward.

We are deeply grateful to all of our professional contributors, who shared invaluable expertise supported by real-world treatment results:

And, of course, to the many clinicians who attended and will soon be delivering Papillon CXB as part of their cancer treatment programmes worldwide.

With another successful year completed, our team now looks ahead to the American Society for Radiation Oncology (ASTRO) Conference in San Francisco from 28 September 2025.

For further information or to discuss Papillon CXB’s clinical applications, please contact:

Mark Davies-Cousins
VP International Sales
mark.davies@arianemedicalsystems.com

SFRO ONCOLOGY CONFERENCE

/in , , /by

17–19 September 2025
Bordeaux, France

Ariane was delighted to attend this year’s SFRO Oncology Conference in Bordeaux, alongside our partners at Clerad.

The conference highlighted a major milestone for the Papillon community. With four new Papillon CXB systems now treating patients and another on the way, France has firmly reclaimed its position as one of the leading countries in the world for the use of Papillon contact brachytherapy. This innovative treatment is increasingly recognised for its impact in rectal cancer, skin cancer, and breast IORT.

Throughout the event, our team engaged with clinicians and specialists to share insights on how Papillon CXB can be integrated into cancer centres, expanding the reach of targeted treatments and improving patient outcomes.

If you would like a full briefing on how Papillon CXB could enhance your cancer treatment programme, please contact:

Mark Davies-Cousins
VP International Sales
mark.davies@arianemedicalsystems.com